Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Claritas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Details : R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 21, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Claritas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : NYX-PCSK9i
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nyrada Reveals Encouraging Cholesterol-Lowering Drug Study Results
Details : According to pre-clinical results, the cells showed an increase in LDL receptor levels and demonstrated equivalency to marketed monoclonal PCSK9 antibody drugs, evolocumab and alirocumab.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2020
Lead Product(s) : NYX-PCSK9i
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable